#United States #Bellevue #Immuno-Oncology #OSR Holdings #Vaximm AG

Dr. Andreas Niethammer Takes the Lead at Vaximm AG

In a significant move for the biotech industry, OSR Holdings, Inc. (NASDAQ: OSRH) has appointed Dr. Andreas Niethammer, M.D., Ph.D., as the new Chief Executive Officer (CEO) of Vaximm AG, effective December 1, 2025. Dr. Niethammer is not just stepping into this role; he is a scientific co-founder and has been instrumental in shaping Vaximm since its inception.

Vaximm AG, a Swiss-German biotech company, is known for pioneering oral T-cell immunotherapies aimed at treating cancer. The company has made great strides in this field, particularly through its lead candidate, VXM01, which targets VEGFR-2 and is currently being tested in first-in-human clinical trials for conditions such as pancreatic cancer and glioblastoma. Dr. Niethammer's pioneering work in oral T-cell vaccination, first published in Nature in 2002, laid the groundwork for these remarkable advancements.

Focus on Combined Immuno-Oncology Strategies

Under Dr. Niethammer's guidance, the focus will shift towards integrating Vaximm's oral vaccination platform with viral oncolysis technologies. These technologies have already shown proof-of-concept in clinical trials and promise to enhance treatment options for patients suffering from renal cell carcinoma (RCC) and other types of advanced solid tumors. The announcement of a forthcoming strategic collaboration will further promote this innovative approach.

Dr. Niethammer expressed his enthusiasm for taking on the CEO role at such a dynamic time for Vaximm, stating, "I am delighted to step into the role of CEO as we enter an exciting new phase where Vaximm's oral vaccination platform can be combined with potent oncolytic and immune-modulating approaches. Our goal is to deliver more durable systemic antitumor responses while maintaining an excellent safety and tolerability profile."

Peter Hwang, CEO of OSR Holdings, lauded Dr. Niethammer’s appointment as a natural progression. He noted that Dr. Niethammer uniquely combines scientific vision with extensive clinical development experience, which is vital for Vaximm’s success moving forward.

The Future of Vaximm AG

Vaximm AG is renowned for its innovative oral T-cell vaccination platform that utilizes live, attenuated bacterial vectors. This sophisticated technology aids in delivering tumor-associated antigens, essentially triggering strong cellular immune responses. The company is dedicated to changing the landscape of cancer treatment and has already shown clinical activity and safety through its lead product.

As Vaximm AG prepares for this next chapter under Dr. Niethammer’s leadership, there is palpable excitement in the air about the future of immuno-oncology. OSR Holdings, as a global healthcare holding company, is poised to leverage this significant appointment to accelerate the development of transformative therapies that could significantly enhance global health outcomes. The future indeed looks promising as the company prepares to unveil new initiatives and partnerships in the months to come.

For more information on Vaximm and its innovative therapies, visit www.OSR-Holdings.com.